Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.35 |
| ▸ | ECE1 | P42892 | 1/20 | 0.35 |
| ▸ | MLYCD | O95822 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.33 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | SELE | P16581 | 1/20 | 0.32 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | FNTB | P49356 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2305835 | 0.81 | KDM4E (0.55) | KDM4EMAP3K5ECE1ALDH1A1TSHR | |
| SCHEMBL14543239 | 0.75 | KDM4E (0.48) | KDM4EMAP3K5TRPM8ALDH1A1TSHR | |
| SCHEMBL269086 | 0.73 | — | — | |
| SCHEMBL12424206 | 0.73 | ALDH1A1 (0.50) | KDM4EMAP3K5MLYCDALDH1A1TDP1 | |
| SCHEMBL30302154 | 0.72 | KDM4E (0.46) | KDM4EMAP3K5ALDH1A1TSHRRAB9A | |
| Hydrochloric Acid SCHEMBL27395585 | 0.72 | KDM4E (0.53) | KDM4EMAP3K5ECE1ALDH1A1TSHR | |
| SCHEMBL306106 | 0.71 | ALDH1A1 (0.53) | KDM4EALDH1A1GRM4MEN1KMT2A | |
| SCHEMBL2311114 | 0.71 | KDM4E (0.50) | KDM4EALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL30302167 | 0.71 | KDM4E (0.44) | KDM4EMAP3K5ALDH1A1TSHRMEN1 | |
| Ethyne SCHEMBL27709832 | 0.70 | KDM4E (0.52) | KDM4EMAP3K5ECE1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389002-A1 | Chiral Indole Compounds and Their Use | ARIAGEN, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| EP-3289876-B1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIV TENNESSEE RES FOUND (US) | 2022-07-20 | — | — | EP | disclosed |
| US-11390621-B2 | Chiral indole compounds and their use | ARIAGEN, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3956327-A1 | CHIRAL INDOLE COMPOUNDS AND THEIR USE | Ariagen, Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| CN-113906021-A | Chiral indole compound and application thereof | 阿里根公司 | 2022-01-07 | — | — | CN | disclosed |
| US-20210188834-A1 | Chiral Indole Compounds and Their Use | ARIAGEN, INC. (US) | 2021-06-24 | — | — | US | disclosed |
| US-10865196-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2020-12-15 | — | — | US | disclosed |
| WO-2020214740-A9 | CHIRAL INDOLE COMPOUNDS AND THEIR USE | ARIAGEN, INC. (US) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020214740-A1 | CHIRAL INDOLE COMPOUNDS AND THEIR USE | ARIAGEN, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| US-10301285-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-8071595-B2 | 1,2-disubstituted heterocyclic compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| EP-2303021-A2 | COMPOUNDS FOR THE TREATMENT OF CANCER | University of Tennessee Research Foundation (US) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010074776-A2 | COMPOUNDS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20100137317-A1 | 1,2-Disubstituted Heterocyclic Compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20090326020-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090326020-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2009-12-31 | — | — | US | disclosed |
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER INC | 2008-04-17 | — | — | US | disclosed |
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER INC | 2008-04-17 | — | — | US | disclosed |
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER INC | 2008-04-17 | — | — | US | disclosed |
| WO-2008004117-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326020-A1 | COMPOUNDS FOR TREATMENT OF CANCER | HCCS, NQO1, CCNY | KDM4E 1473/4885MAP3K5 4294/4885CLK1 3874/4885 |
| US-10865196-B2 | Compounds for treatment of cancer | CYP19A1, CYP17A1, SOX18 | KDM4E 260/4885MAP3K5 1679/4885CLK1 4521/4885 |
| US-10301285-B2 | Compounds for treatment of cancer | CYP19A1, CYP17A1, SOX18 | KDM4E 260/4885MAP3K5 1679/4885CLK1 4521/4885 |
| US-20210188834-A1 | Chiral Indole Compounds and Their Use | IDO1, IDO2, INMT | KDM4E 1410/4885MAP3K5 2197/4885CLK1 1593/4885 |
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PDE5A, PDE3B, PDE12 | KDM4E 636/4885MAP3K5 892/4885CLK1 2394/4885 |
| US-20220389002-A1 | Chiral Indole Compounds and Their Use | IDO1, IDO2, INMT | KDM4E 1410/4885MAP3K5 2197/4885CLK1 1593/4885 |
| US-11390621-B2 | Chiral indole compounds and their use | IDO1, IDO2, INMT | KDM4E 1410/4885MAP3K5 2197/4885CLK1 1593/4885 |
| US-20100137317-A1 | 1,2-Disubstituted Heterocyclic Compounds | PDE12, PDE7A, PDE10A | KDM4E 1865/4885MAP3K5 1388/4885CLK1 1969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.